About IMARCFor more than 5 years, the International Market Analysis Research and Consulting Group hasbeen a leading adviso...
About The ReportIMARC’s new report “France Diabetes Market Forecast 2011-2016” provides an analyticaland statistical insig...
Why should you buy this report?   Gain a deeper understanding about the prevalence, diagnosis and treatment of diabetes in...
Table of Contents1     Executive Summary ---------------------------------------------------------------------------------...
List of FiguresFigure 2-1: France: Number of Diabetes Patients* (in 000’s), 2010, 2015, 2020, 2025 & 2030................ ...
List of TablesTable 1-1: France: Oral Antidiabetics & Insulin Definitions....................................................
Prices and Order Information  Electronic Access         Electronic Access           CD-ROM Mail Delivery    Hard Copy Mail...
France Diabetes Market Forecast
Upcoming SlideShare
Loading in …5
×

France Diabetes Market Forecast

293 views
243 views

Published on

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
293
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

France Diabetes Market Forecast

  1. 1. About IMARCFor more than 5 years, the International Market Analysis Research and Consulting Group hasbeen a leading advisor on management strategy and market research worldwide. We partnerwith clients in all sectors and regions to identify their highest-value opportunities, address theirmost critical challenges, and transform their businesses.IMARCs information products include major market, scientific, economic and technologicaldevelopments for business leaders in pharmaceutical, industrial, and high technologyorganizations. Market forecasts and industry analysis for biotechnology, advanced materials,pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processingmethods are at the top of the companys expertise.IMARC’s tailored approach combines unfathomable insight into the dynamics of companies andmarkets with close cooperation at all levels of the client organization. This ensures that ourclients achieve unmatchable competitive advantage, build more proficient organizations, andsecure lasting results.imarc©
  2. 2. About The ReportIMARC’s new report “France Diabetes Market Forecast 2011-2016” provides an analyticaland statistical insight into the French diabetes market. The report provides both current andfuture trends in the prevalence, demographical breakup, diagnosis and treatment of diabetesin France. The report has segmented the French diabetes market into two segments – Insulinand the Oral Antidiabetics market. For each of the aforementioned categories, the reportprovides historical and future market sales of key classes, key companies, key drugs and keymolecules.The research study serves as an exceptional tool to understand the market trends,therapeutic structure, competitive structure and the outlook of the French diabetes markettill 2016. This report can serve as an excellent guide for investors, researchers, consultants,marketing strategists and all those who are planning to foray into the French diabetes marketin some form or the other.Key Questions Answered in this Report: What is the size and demographical breakup of the diabetes population in France? What are the current and future diagnosis and drug treatment rates of diabetes in France? How has the diabetes market behaved since 2005 and what are the expected trends till 2016? What has been the historical performance of the French Insulin market during 2005-2010 and its outlook till 2016? What has been the performance of top classes, top players, top molecules and top drugs in the Insulin market during 2005-2010? What has been the historical performance of the Oral Antidiabetics market during 2005- 2010 and its outlook till 2016? What has been the performance of top classes, top players, top molecules and top drugs in the Oral Antidiabetics market during 2005-2010?imarc©
  3. 3. Why should you buy this report? Gain a deeper understanding about the prevalence, diagnosis and treatment of diabetes in France and identify your potential patient pool. Analyze the historical, current and future trends in the Insulin and Oral Antidiabetics market to identify potential classes, drugs, partners and competitors for market entry and expansion plans. Develop Investment strategies by identifying companies that have been the biggest winners and losers in the French Insulin and Oral Antidiabetics market. Gain an insight into future market events such as biosimilars and new product launches.Classes Covered:Fast acting Insulins, Long acting Insulins, Intermediate and Fast acting Insulins, Intermediateacting Insulins, Biguanides, Glitazone and Biguanide combinations, Biguanide andSulphonylurea combinations, Glinides, Sulphonylureas, Glitazones, DPP-IV Inhibitors, Glp-1Agonists, Alpha-Glucosidase Inhibitors, DPP-IV Inhibitor and Biguanide combinations,Glitazone and Sulphonylurea combinations, SGLT Inhibitors, SGLT Inhibitor and Biguanidecombinations, PTP1B Inhibitors and all other Oral Antidiabetic classes.Information Sources:Information has been sourced from both primary and secondary sources: Primary sources include industry surveys and face to face/telephonic interviews with physicians and industry experts. Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, Industry Portals, government sources and access to more than 4000 paid databases.Forecasting Methodology:IMARC generates its product and market forecasts utilizing its extensive database ofmacroeconomic and sector specific data. The initial baseline forecast is generated with themost recent market data. After an initial baseline forecast, all future macroeconomic andsector specific events and assumptions are taken into account to generate the final forecast.imarc©
  4. 4. Table of Contents1 Executive Summary ---------------------------------------------------------------------------------------------------- 102 Epidemiology ------------------------------------------------------------------------------------------------------------- 13 2.1 Total Diabetes Patients ----------------------------------------------------------------------------------------- 13 2.2 Patients by Gender ----------------------------------------------------------------------------------------------- 14 2.3 Patients by Age Group ------------------------------------------------------------------------------------------ 15 2.4 Diagnosed and Drug Treated Population ----------------------------------------------------------------- 163 Market Dynamics -------------------------------------------------------------------------------------------------------- 17 3.1 Diabetes Market --------------------------------------------------------------------------------------------------- 17 3.1.1 Current Trends (2005–2010) ------------------------------------------------------------------------------ 17 3.1.2 Market Forecast (2011-2016) ----------------------------------------------------------------------------- 18 3.2 Insulin Market ------------------------------------------------------------------------------------------------------ 19 3.2.1 Current Trends (2005-2010) ------------------------------------------------------------------------------ 19 3.2.1.1 Market by Class ------------------------------------------------------------------------------------------- 20 3.2.1.2 Market by Molecule -------------------------------------------------------------------------------------- 20 3.2.1.3 Top Players ------------------------------------------------------------------------------------------------ 22 3.2.1.4 Top Drugs -------------------------------------------------------------------------------------------------- 23 3.2.2 Forecast (2011-2016) --------------------------------------------------------------------------------------- 24 3.3 Oral Antidiabetics------------------------------------------------------------------------------------------------- 26 3.3.1 Current Trends (2005-2010) ------------------------------------------------------------------------------ 26 3.3.1.1 Market by Class ------------------------------------------------------------------------------------------- 28 3.3.1.2 Top Players ------------------------------------------------------------------------------------------------ 30 3.3.1.3 Top Drugs -------------------------------------------------------------------------------------------------- 32 3.3.2 Forecast (2011-2016) --------------------------------------------------------------------------------------- 34imarc©
  5. 5. List of FiguresFigure 2-1: France: Number of Diabetes Patients* (in 000’s), 2010, 2015, 2020, 2025 & 2030................ 13Figure 2-2: France: Breakup of Diabetes Patients by Gender (in 000’s), 2010, 2015, 2020, 2025 & 203014Figure 2-3: France: Breakup of Diabetes Patients by Gender (in %) 2010, 2015, 2020, 2025 & 2030 ..... 14Figure 2-4: France: Breakup of Diabetes Patients by Age Group (in 000’s), 2010, 2015, 2020, 2025 &2030 ...................................................................................................................................................... 15Figure 2-5: France: Breakup of Diabetes Patients by Age Group (in %) 2010, 2015, 2020, 2025 & 2030 15Figure 2-6: France: Diagnosed & Drug Treated Share of Population Forecast (in %) 2010, 2015 & 2020 16Figure 3-1: France: Diabetes Market (in Million US$), 2005-2010 ........................................................... 17Figure 3-2: France: Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2005-2010........ 17Figure 3-3: France: Diabetes Market Forecast (in Million US$), 2011-2016 ............................................ 18Figure 3-4: France Diabetes Market: Breakup of Insulin and Oral Antidiabetics (in %), 2011-2016.......... 18Figure 3-5: France: Insulin Market (in Million US$), 2005-2010 .............................................................. 19Figure 3-6: France: Breakup of Insulin Market by Class (in %), 2005-2010 ............................................. 20Figure 3-7: France: Insulin Market: Share by Molecules (in %), 2005-2010 ........................................... 21Figure 3-8: France: Insulin Market: Share of Key Players (in %), 2005-2010 ......................................... 22Figure 3-9: France: Insulin Market: Sales of Key Drugs (in %), 2005-2010 ............................................. 23Figure 3-10: France: Insulin Market Forecast (in Million US$), 2011-2016 .............................................. 25Figure 3-11: France: Oral Antidiabetics Market, (in Million US$), 2005-2010 .......................................... 27Figure 3-12: France: Oral Antidiabetics Market: Share by Class (in %), 2005-2010 ................................ 29Figure 3-13: France: Oral Antidiabetics Market: Share of Key Players (in %), 2005-2010 ...................... 32Figure 3-14: France: Oral Antidiabetics Market: Share of Key Drugs (in %), 2005-2010.......................... 33Figure 3-15: France: Oral Antidiabetics Market Forecast (in Million US$), 2011-2016 ............................. 35Figure 3-16: France: Oral Antidiabetics Market: Share by Class Forecast (in %), 2010-2016 .................. 36imarc©
  6. 6. List of TablesTable 1-1: France: Oral Antidiabetics & Insulin Definitions........................................................................ 8Table 2-1: France: Diagnosed & Drug Treated Population (in Millions), 2010, 2015 & 2020 .................... 16Table 3-1: France: Breakup of Insulin Market by Class (in Million US$), 2005-2010................................ 20Table 3-2: France: Insulin Market: Sales by Molecule (in Million US$), 2005-2010 ................................ 21Table 3-3: France: Insulin Market: Sales of Key Players (in Million US$), 2005-2010............................. 22Table 3-4: France: Insulin Market, Sales of Top Drugs (in Million US$), 2005-2010 ................................ 23Table 3-5: France: Oral Antidiabetics Market: Sales by Class (in Million US$), 2005-2010 ..................... 29Table 3-6: France: Oral Antidiabetics Market: Sales of Key Players (in Million US$), 2005-2010 ........... 31Table 3-7: France: Oral Antidiabetics Market, Sales of Top Drugs (in Million US$), 2005-2010 ............... 33Table 3-8: France: Oral Antidiabetics Market, New Drug Launches (2011-2016) .................................... 34Table 3-9: France: Oral Antidiabetics Market by Class Forecast, (in Million US$), 2010, 2013 & 2016 .... 36imarc©
  7. 7. Prices and Order Information Electronic Access Electronic Access CD-ROM Mail Delivery Hard Copy Mail Delivery(Single User License) (Multi User License) (Single User License) (Single User License) US$ 750 US$ 1300 US$ 900 US$ 900 For more information visit: http://www.imarcgroup.com/france-diabetes-market-forecast-2011-2016/ To buy the complete report or to get a free sample: Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America) Email:sales@imarcgroup.com

×